In times of high uncertainty like this 2020 year, it is necessary to celebrate and savor the victories. We want to congratulate our portfolio company Sleepiz for its well-deserved success in winning collaboration with one of the three Executive MBA cohorts at the beginning of 2021
Collaboration Funding Innovation Press Release Regulatory
Revolutionising biomedical data sharing and AI-driven healthcare solutions
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
Investment Press Release
hemotune makes a significant step forward: advancing into clinical trials after completing CHF 14 million Series B2 round
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
Diversity Hemex Team
We welcome David to the team!
HEMEX contribution for preparing tomorrow's leaders!
Continue reading
Investment Press Release
Driving the future of non-surgical endometriosis diagnosis: Hera Biotech acquires Scailyte’s endometriosis diagnostic assets
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
Hemex Team
Graphic Design Internship at HEMEX
Noémie is a student at FMS Muttenz. She completed a two-week internship at HEMEX focusing [...]
Continue readingPress Release
ASPIVIX Reports Positive First-In-Women Results Using Novel Suction-Based Cervical Device in IUD Procedures
Our portfolio company ASPIVIX SA announced last week the completion of and interim analysis results from its Phase I first-in-women trial. The two-phase ADVANCE Women trial is assessing the usability, efficacy, and safety of the investigational CAREVIX, the innovative device designed as a modern and gentler alternative. Warmest congratulations on your achievement, ASPIVIX!
